PALO ALTO, Calif., Nov. 10, 2010 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today the launch of a completely redesigned corporate website with greatly expanded content and an enhanced layout. The new website provides access to a wealth of information through improved navigation tools, and highlights the Company's scientific and industry leadership in the development and commercialization of novel cell-based therapeutics and tools for stem cell-based research and drug discovery. The new website can be found at .
In addition to showcasing StemCells' people, science and technologies, the new website provides users with easier access to key online content associated with the Company's scientific achievements and therapeutic product development programs targeting the central nervous system and the liver.
The Company's enabling tools and technologies are also featured more prominently on the new website through specialized sections dedicated to its comprehensive drug discovery and development platform and its SC Proven® media and reagent products for stem cell researchers. SC Proven customers who visit either the new website or will find online ordering more convenient through the addition of a shopping cart and expanded product information. Prospective pharmaceutical and biotechnology partners will also find information on how the Company's integrated drug discovery and development platform may help them identify lead candidates with greater efficiency and higher probability of success.
For investors, the website features a November 2010 Letter to Investors from President & CEO Martin McGlynn. The letter is accessible through the CEO Corner section of the new website, which will include occasional commentary from Mr. McGlynn on various company and industry topics. An updated Investors section also offers broader investor-targeted information along with added tools and functionality.
Enhanced visual content and rich media additions are also included throughout the new website, including a series of video clips highlighting the potential of the Company's HuCNS-SC® lead product candidate (purified human neural stem cells) to treat a broad range of neurological conditions including spinal cord injury. These videos feature commentary by Martin McGlynn; Irving Weissman, MD, Chair of the Scientific Advisory Board and Director, StemCells, Inc.; Aileen Anderson, PhD, Associate Professor in the Departments of Physical Medicine and Rehabilitation, and Anatomy and Neurobiology at UC Irvine; and Stephen Huhn, MD, FACS, FAAP, Vice President & Head of the CNS Program, StemCells, Inc.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. In its therapeutic product development programs, StemCells is targeting diseases of the central nervous system and the liver. The Company's lead product candidate, HuCNS-SC® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders in children, and in preclinical development for spinal cord injury and retinal disorders such as age-related macular degeneration. StemCells also markets stem cell research products, including media and reagents, under the SC Proven®brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at .
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the future business operations of StemCells, Inc. (the "Company"). The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and in its subsequent reports on Form 10-Q and Form 8-K.
CONTACT: StemCells, Inc. Investor Inquiries Megan Meloni (650) 475-3105 Russo Partners Media Ian Stone (619) 528-2220 David Schull (212) 845-4271